Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information
Autoimmune disease
Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor increased autoantibody levels and resulted in more severe disease compared with vehicle. Next steps include determining the cell types and components of IDO biology involved in an autoimmune response. SciBX 5(10); doi:10.1038/scibx.2012.247 Published online March 8, 2012 Patent pending for undisclosed indications; licensing status undisclosed Ravishankar, B. et al. Proc. Natl. Acad. Sci. USA; published online Feb. 21, 2012; doi:10.1073/pnas.1117736109 Contact: Tracy L. McGaha, Georgia Health Sciences University, Augusta, Ga. e-mail: tmcgaha@georgiahealth.edu
Cancer
Brain cancer Ubiquitin specific peptidase 15 (USP15); transforming growth factor-b receptor 1 (TGFBR1; ALK5) Studies in patient samples suggest inhibiting USP15 could help treat glioblastoma by blocking transforming growth factor-b (TGFB; TGFb) signaling. In glioblastoma samples, USP15 expression was positively correlated with TGFBR1 levels and USP15 amplification was correlated with a negative prognosis. In mice injected with patient-derived glioblastoma neurospheres, small hairpin RNA knockdown of USP15 lowered TGFBR1 levels and tumor growth compared with no knockdown. Next steps could include screening for specific USP15 inhibitors. SciBX 5(10); doi:10.1038/scibx.2012.248 Published online March 8, 2012 Patent and licensing status unavailable Eichhorn, P.J.A. et al. Nat. Med.; published online Feb. 19, 2012; doi:10.1038/nm.2619 Contact: Joan Seoane, Vall d'Hebron University Hospital, Barcelona, Spain e-mail: jseoane@vhio.net
Cancer Anthrax toxin receptor 1 (ANTXR1; TEM8) Studies in mice

Read the full 2597 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE